Research Profile (QSAM) – Stock Day Media

Login Streaming News Register

Special Research Report

HOW TO USE DISCUSSION BOARDS

Office Hours: 9:00 AM - 4:00 PM (EST) Monday - Thursday Call: 602-821-1102

Featured News QSAM

QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals; Receives $2 Million Pre-Closing Collaboration and Option Fee

QSAM Biosciences Provides Update to Shareholders on Phase 1 Progress and Preliminary Clinical Data

QSAM Biosciences Expands its Study of CycloSam® in the Treatment of Bone Cancer; Opens Patient Enrollment at Key Chicago Center, Insight Hospital and Medical Center

QSAM Biosciences Receives Clearance from FDA to Expand Enrollment Criteria in its Phase 1 Study of CycloSam® Targeting Metastatic Bone Cancer

QSAM Biosciences Recruits the Ellis Fischel Cancer Center at the University of Missouri as Clinical Trial Site to Further Expand and Advance the Study of CycloSam® for Bone Cancer

Discussion QSAM

Login -or- Register to join the discussion.

Stock Day Media may receive direct compensation of $500 to $10,000 for content and or advertisements, that may be subject to disclaimer pursuant to Section 17(b) of the Securities Act of 1933. For those instances where it contains company or stock-specific mention, we provide the following list of compensation received in order to ensure full disclosure and transparency.